Backgrounds: The purpose of this study is to present our clinical experience using the Ilizarov bone transfer technique and free-flap technique in the reconstruction of large tibial bone and soft tissue defects, including an evaluation of both the management of postoperative complications and long-term outcomes. Methods: From January 2010 to May 2020, 72 patients with tibia bone and soft tissue defects were retrospectively evaluated. Either an anterolateral thigh perforator flaps (ALTP) or latissimus dorsi musculocutaneous flaps (LD), solely or in combination, were used to cover soft tissue defects. Once the flap was stabilized, an Ilizarov external fixator was applied to the limb. Follow-up was postoperatively performed at 1, 3, 6, 9, and 12 months. Results: Postoperatively, there were two cases of total and five of partial flap necrosis, and two cases of subcutaneous ulcers, which were caused by vascular crisis, infection, and hematoma, respectively. All the patients underwent Ilizarov external fixator surgery after flap recovery. A total of 16 complications occurred, including 3 cases of simple needle tract infection (antibiotic treatment) and 13 cases of complications requiring reoperation. A correlation factor analysis revealed that the main factors affecting the healing time were the defect length and operative complications. All patients with complications treated with the vascularized iliac flap eventually healed completely. Conclusions: The Ilizarov method used together with an ALTP, LD, or a combination thereof yields good clinical results for repairing large bone and soft tissue defects of the tibia, thus reducing the incidence of amputations. However, longer treatment times may be involved, and postoperative complications can occur. The vascularized iliac flap may be a suitable choice for the treatment of postoperative complications of this type of Ilizarov bone transport.
4 December 2023 in Theoretical and Natural Science
Sunitinib, also known as the free base of sunitinib malate, is an innovative oral agent used in the treatment of tumors. It functions by inhibiting various members of the receptor tyrosine kinase (RTK) family, which possess a split kinase structural domain. These members include vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3, platelet-derived growth factor receptors (PDGFR) α and β, stem cell factor receptors, FMS-like tyrosine kinase 3, colony-stimulating factor 1 receptor, and BCR/ABL fusion genes. This paper briefly introduces the research background, pharmacological activity and toxicity of sunitinib, sorting out the incidence and pathogenesis of the diseases it is targeted to treat, and its regulatory mechanism in treating the diseases, etc., summarising several synthetic routes of sunitinib researched by the previous researchers, and at the same time analysing and evaluating the synthetic routes and suggesting the synthetic routes, summing up and proposing the outlook of its subsequent research contents and directions, providing references and help to the research on sunitinib afterward.